Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Structure Therapeutics Inc. before investing.

In this article, we go over a few key elements for understanding Structure Therapeutics Inc.’s stock price such as:

• Structure Therapeutics Inc.’s current stock price and volume
• Why Structure Therapeutics Inc.’s stock price changed recently
• Upgrades and downgrades for GPCR from analysts
• GPCR’s stock price momentum as measured by its relative strength

About Structure Therapeutics Inc. (GPCR)

Before we jump into Structure Therapeutics Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in preclinical trial to treat obesity; ANPA-0073, an oral small molecule agonist targeting the apelin, which is phase 2 ready for selective weight loss or muscle-sparing weight loss; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Want to learn more about Structure Therapeutics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Structure Therapeutics Inc..

Structure Therapeutics Inc.’s Stock Price as of Market Close

As of December 05, 2025, 4:00 PM, CST, Structure Therapeutics Inc.’s stock price was $34.560.

Structure Therapeutics Inc. is up 5.21% from its previous closing price of $32.850.

During the last market session, Structure Therapeutics Inc.’s stock traded between $32.510 and $35.810. Currently, there are approximately 58.49 million shares outstanding for Structure Therapeutics Inc..

Structure Therapeutics Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Structure Therapeutics Inc. Stock Price History

Structure Therapeutics Inc.’s (GPCR) price is currently down 3.49% so far this month.

During the month of December, Structure Therapeutics Inc.’s stock price has reached a high of $36.090 and a low of $30.940.

Over the last year, Structure Therapeutics Inc. has hit prices as high as $40.290 and as low as $13.220. Year to date, Structure Therapeutics Inc.’s stock is up 27.43%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Structure Therapeutics Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 05, 2025, there were 0 analysts who downgraded Structure Therapeutics Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Structure Therapeutics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Structure Therapeutics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Structure Therapeutics Inc. (GPCR) by visiting AAII Stock Evaluator.

Relative Price Strength of Structure Therapeutics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 05, 2025, Structure Therapeutics Inc. has a weighted four-quarter relative price strength of 12.86%, which translates to a Momentum Score of 86 and is considered to be Very Strong.

Want to learn more about how Structure Therapeutics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Structure Therapeutics Inc. Stock Price: Bottom Line

As of December 5, 2025, Structure Therapeutics Inc.’s stock price is $34.560, which is up 5.21% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Structure Therapeutics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.